DOI QR코드

DOI QR Code

A Systematic Review of Cervical Cancer Incidence and Mortality in the Pacific Region

  • Obel, J. ;
  • Souares, Y. ;
  • Hoy, D. ;
  • Baravilala, W. ;
  • Garland, S.M. ;
  • Kjaer, S.K. ;
  • Roth, A.
  • Published : 2014.11.28

Abstract

This study provides the first systematic literature review of cervical cancer incidence and mortality as well as human papillomavirus (HPV) genotype prevalence among women with cervical cancer in the Pacific Island countries and territories. The cervical cancer burden in the Pacific Region is substantial, with age standardized incidence rates ranging from 8.2 to 50.7 and age standardized mortality rate from 2.7 to 23.9 per 100,000 women per year. The HPV genotype distribution suggests that 70-80% of these cancers could be preventable by the currently available bi- or quadrivalent HPV vaccines. There are only few comprehensive studies examining the epidemiology of cervical cancer in this region and no published data have hitherto described the current cervical cancer prevention initiatives in this region.

Keywords

Pacific;cervical cancer;human papillomavirus

References

  1. Ali H, Donovan B, Wand H, et al (2013). Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ, 346, 2032. https://doi.org/10.1136/bmj.f2032
  2. Brotherton JM, Friedman M, May CL, et al (2011). Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet, 377, 2085-92. https://doi.org/10.1016/S0140-6736(11)60551-5
  3. Broutet N, Lehnertz N, Mehl G, et al (2013). Effective health interventions for adolescents that could be integrated with human papillomavirus vaccination programs. J Adolesc Health, 53, 6-13. https://doi.org/10.1016/j.jadohealth.2013.02.022
  4. Brown DR, Kjaer SK, Sigurdsson K, et al (2009). The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis, 199, 926-35. https://doi.org/10.1086/597307
  5. Clifford GM, Smith JS, Aguado T, Franceschi S (2003). Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer, 89, 101-5. https://doi.org/10.1038/sj.bjc.6601024
  6. Secretariat of the Pacific Community (2011). Tahiti Nui Declaration [Online]. Available: http://www.spc.int/images/publications/ef/Corporate/ef-tahiti-nui- declaration.pdf (Accessed 10th of december 2013).
  7. Denny L, Anorlu R (2012). Cervical cancer in Africa. Cancer Epidemiol Biomarkers Prev, 21, 1434-8. https://doi.org/10.1158/1055-9965.EPI-12-0334
  8. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  9. Fesenfeld M, Hutubessy R, Jit M (2013). Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine, 31, 3786-804. https://doi.org/10.1016/j.vaccine.2013.06.060
  10. Foliaki S, Best D, Akau'ola S, et al (2011). Cancer incidence in four pacific countries: Tonga, Fiji Islands, Cook Islands and Niue. Pac Health Dialog, 17, 21-32.
  11. Garland SM, Bhatla N, Ngan HY (2012). Cervical cancer burden and prevention strategies: Asia Oceania perspective. Cancer Epidemiol Biomarkers Prev, 21, 1414-22. https://doi.org/10.1158/1055-9965.EPI-12-0164
  12. GAVI. Human Papilloma Virus vaccine support [Online]. Available: http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccine-support/ (Accessed 9th of December 2013).
  13. Goldie SJ, Diaz M, Kim SY, et al (2008). Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine, 26, 17-29.
  14. Haddock RL, Talon RJ, Whippy HJ (2006). Ethnic disparities in cancer mortality among residents of Guam. Asian Pac J Cancer Prev, 7, 411-4.
  15. IARC (2012). GLOBOCAN: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 [Online]. Available: http://globocan.iarc.fr/Pages/online.aspx (Accessed 31st August 2014).
  16. Institute for Health Metrics and Evaluation (2013). Global Burden of Disease Study 2010 Results by Cause and Region 1990-2010 [Online]. Available: http://ghdx.healthmetricsandevaluation.org/record/global-burden-disease-study-2010-gbd-2010-results-cause-1990-2010 (Accessed May 2 2013).
  17. Knaul FM, Bhadelia A, Gralow J, et al (2012). Meeting the emerging challenge of breast and cervical cancer in low- and middle-income countries. Int J Gynaecol Obstet, 119, 85-8. https://doi.org/10.1016/j.ijgo.2012.05.016
  18. Kuehn R, Fong J, Taylor R, Gyaneshwar R, Carter K (2012). Cervical cancer incidence and mortality in Fiji 2003-2009. Aust N Z J Obstet Gynaecol, 52, 380-6. https://doi.org/10.1111/j.1479-828X.2012.01461.x
  19. Law I, Fong J, Buandromo EM, et al (2013). The high burden of cervical cancer in Fiji, 2004-07. Sex Health, 10, 171-8. https://doi.org/10.1071/SH12135
  20. Levin CE, Van Minh H, Odaga J, et al (2013). Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bulletin World Health Organization, 91, 585-92. https://doi.org/10.2471/BLT.12.113837
  21. Moore MA, Baumann F, Foliaki S, et al (2010). Cancer epidemiology in the Pacific islands-past, present and future. Asian Pac J Cancer Prev, 1, 99-106.
  22. Parkin DM, Louie KS, Clifford G (2008). Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine, 26, 1-16.
  23. Paavonen J, Naud P, Salmeron J, et al (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet, 374, 301-14. https://doi.org/10.1016/S0140-6736(09)61248-4
  24. Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, Vermund SH (2012). Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential. Cancer Prev Res, 5, 11-7. https://doi.org/10.1158/1940-6207.CAPR-11-0540
  25. Tabone T, Garland SM, Mola G, et al (2012). Prevalence of human papillomavirus genotypes in women with cervical cancer in Papua New Guinea. Int J Gynaecol Obstet, 117, 30-2. https://doi.org/10.1016/j.ijgo.2011.11.022
  26. Tabrizi SN, Law I, Buadromo E, et al (2011). Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Fiji. Sex Health, 8, 338-42. https://doi.org/10.1071/SH10083
  27. Tabrizi SN, Brotherton JM, Kaldor JM, et al (2014). Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect dis, [Epub ahead of print].
  28. Vodonaivalu L, Bullen C (2013). Trends in cervical cancer in Fiji, 2000-2010. Public Health Action, 3, 68-71. https://doi.org/10.5588/pha.12.0066
  29. WHO 2009. Human papillomavirus vaccines: WHO position paper. Biologicals, 37, 338-44. https://doi.org/10.1016/j.biologicals.2009.04.005

Cited by

  1. Prognostic Evaluation of Tumor-Stroma Ratio in Patients with Early Stage Cervical Adenocarcinoma Treated by Surgery vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4363
  2. Parameters Involved in Autophosphorylation in Chronic Myeloid Leukemia: a Systems Biology Approach vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5273
  3. Barriers to Cervical Screening among Pacific Women in a New Zealand Urban Population vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1565
  4. Mapping HPV Vaccination and Cervical Cancer Screening Practice in the Pacific Region-Strengthening National and Regional Cervical Cancer Prevention vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3435
  5. Extended Field Radiotherapy With or Without Chemotherapy in Patients with Cervical Cancer and Positive Para-Aortic Lymph Nodes: a Single Institution Retrospective Review vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3827
  6. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells vol.15, pp.1, 2016, https://doi.org/10.3892/mmr.2016.6003
  7. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression vol.37, pp.5, 2016, https://doi.org/10.1007/s13277-015-4416-9
  8. Cervical cancer in Iran: integrative insights of epidemiological analysis vol.8, pp.3, 2018, https://doi.org/10.1051/bmdcn/2018080318
  9. Up-regulation of inflammation-related LncRNA-IL7R predicts poor clinical outcome in patients with cervical cancer vol.38, pp.3, 2018, https://doi.org/10.1042/BSR20180483
  10. Innovative approaches to cervical cancer screening in low- and middle-income countries vol.21, pp.3, 2018, https://doi.org/10.1080/13697137.2018.1439917